Boosted by Covance Acquisition, LabCorp Posts 48 Percent Revenue Growth in Q4

Feb 18, 2016

|

NEW YORK (GenomeWeb) – Laboratory Corporation of America today reported fourth quarter revenue growth of 48 percent driven by its acquisition of Covance.

The Burlington, North Carolina-based clinical testing services firm had revenues of $2.24 billion in Q4, up from $1.51 billion in the fourth quarter of 2014 and above the average Wall Street estimate of $2.22 billion.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Letters Urge Review of Decision to End Coronavirus Grant

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

US Concerns Over BGI Testing in Middle East

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

Confidence Boost

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

Science Studies Describe Machine Learning Algorithm to Speed Mendelian Diagnoses, Safe Drug Response Gene, More

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.

Featured White Papers

NGS-Based Target Capture for SARS-CoV-2 Detection and Characterization

Best Practices for Point of Care (POC) Product Development

Seeing Beyond the Limit: Detect Residual Disease and Assess Treatment Response

A Personalized, Tumor-Informed Approach to Detect Molecular Residual Disease With High Sensitivity and Specificity

May

27

Featured Webinar

Identifying Molecular Drivers of Cancer via Comprehensive Sequencing of a Large Cohort with Matched Germline and Clinical Data

M2Gen’s Oncology Research Information Exchange Network (ORIEN) Avatar Research Program collects and studies consented cancer patients’ biospecimens and companion clinical information for the development of improved oncology treatments.

Jun

04

Featured Webinar

COVID-19 Testing, Treatment and Future Outlook

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.

Menu

Boosted by Covance Acquisition, LabCorp Posts 48 Percent Revenue Growth in Q4

To read the full story....

Breaking News

People in the News: Tony Serafini-Lamanna, Martin Chavez, Sun Kim, Oved Amitay, More

In Brief This Week: ArcherDX, Sherlock Biosciences, Caris Life Sciences, and More

New Products Posted to GenomeWeb: Aalto Bio Reagents, Thermo Fisher, Oxford Immunotec, More

BioCore, SolGent, Seasun Get FDA Emergency Use Authorizations for Coronavirus Tests

P23 Labs Receives FDA Emergency Use Authorization for SARS-CoV-2 Test

Northern, Southern Italian Populations Began to Diverge Genetically Thousands of Years Ago

The Scan

Letters Urge Review of Decision to End Coronavirus Grant

US Concerns Over BGI Testing in Middle East

Confidence Boost

Science Studies Describe Machine Learning Algorithm to Speed Mendelian Diagnoses, Safe Drug Response Gene, More

Featured White Papers

Identifying Molecular Drivers of Cancer via Comprehensive Sequencing of a Large Cohort with Matched Germline and Clinical Data

COVID-19 Testing, Treatment and Future Outlook

What's Popular?

Head-to-Head Comparisons of Commercial SARS-CoV-2 MDx Tests Point to Few Differences in Accuracy

P23 Labs Receives FDA Emergency Use Authorization for SARS-CoV-2 Test

BioCore, SolGent, Seasun Get FDA Emergency Use Authorizations for Coronavirus Tests

SeqOne Looks to Support NGS-Based COVID-19 Testing to Accelerate Pandemic Screening, Tracing

Color Receives FDA Emergency Use Authorization for COVID-19 Test Using Isothermal Amplification

Sponsorships